CODA Biotherapeutics collaborates with the Facial Pain Research Foundation to develop treatments for neuropathic pain

BY      |     May 20, 2020

CODA Biotherapeutics, a biopharmaceutical company developing a gene therapy approach for the treatment of neurological diseases, announced the formation of a strategic partnership with the Facial Pain Research Foundation with the goal to identify and develop potential new therapies and cures for trigeminal neuralgia and related neuropathic pain.

More specifically, in the framework of this collaboration, the Facial Pain Research Foundation will support preclinical research of CODA’s chemogenetically controlled inhibitory ion channels in neuropathic pain.

Read the press release here.

Read more about CODA Biotherapeutics here.

Read more about Facial Pain Research Foundation here.

Image by Arek Socha from Pixabay.

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.